Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2011

View Archived Issues

Promising data disclosed from PEPPER trial of Pantera Lux paclitaxel-releasing balloon

New activators of nuclear receptor related 1 receptor claimed

In vitro profile supports first-in-human study of GSK-2336805 for hepatitis C

HM-781-36B displays potent inhibitory effects in erbB-1-dependent tumors

Treatment of hepatitis C with IDX-184 is not linked to resistance mutations

ADVENTRX acquires SynthRX and poloxamer-188

Czech researchers present new platinum complexes with antitumor activity

Niacin reduces phosphate levels in subjects with hyperphosphatemia due to hemodialysis

Viralytics cleared to dose final patient group in phase I Cavatak study

Delcath receives CE mark for Hepatic Chemosat delivery system

Bayer's oral anticoagulant rivaroxaban submitted for Japanese approval

Takeda to participate in phase III trial of Amgen's AMG-479 in metastatic pancreatic cancer

Terumo expands blood management business with acquisition of CaridianBCT

Debiopharm and Augifene Discovery Technologies partner for Debio-1142

S*BIO doses first patients in phase II trial of SB-1518 in advanced lymphoid malignancies

Quest PharmaTech and Hemispherx to study combinatorial immunotherapy technology

SDD-formulated bardoxolone methyl shows promise in patients with diabetes and chronic kidney disease

Humanized MAb reverses dabigatran-induced anticoagulation in preclinical study

Preclinical and clinical data presented on TRIN-2755 for solid tumors/sarcomas

Novel lysophospholipid S1P1 receptor agonists described by Almirall

N30 Pharma presents new inhibitors of alcohol dehydrogenase class-3

ChemoCentryx presents new CMKLR1 receptor ligands

CHMP adopts positive opinion on Avastin/Xeloda combination in metastatic breast cancer

FDA approves Actemra for systemic juvenile idiopathic arthritis

CHMP recommends approval of once-weekly exenatide for type 2 diabetes

Active Biotech and Ipsen to codevelop and commercialize tasquinimod for cancer

FDA requests additional trial for Lilly's liprotamase NDA in exocrine pancreatic insufficiency

ARCA biopharma gains worldwide rights to genetic markers for chronic heart failure candidate Gencaro

Pfizer reports topline data from phase III ORAL Scan trial of tofacitinib in rheumatoid arthritis

Amarin's phase III ANCHOR trial of AMR-101 meets primary endpoint

Teva Pharma's lansoprazole delayed-release ODT withdrawn from distribution

CHMP recommends approval of dabigatran etexilate for prevention of stroke in patients with AF

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026